Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-40 plus bortezomib dose-escalation study in relapsed or refractory multiple myeloma
NL-OMON31502Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Nov 2008
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dacetuzumab and bortezomib in multiple myeloma (MM), sponsored by Genentech. Primary endpoint: Occurrence and nature of dose-limiting toxicities. Started Nov 2008; status: recruiting.
02
Drugs
dacetuzumabbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON31502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31502.